Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ethan S. Lavi"'
Publikováno v:
PLoS ONE, Vol 19, Iss 7 (2024)
Externí odkaz:
https://doaj.org/article/b7fbf51be075430f8db959fa0b50ecd8
Publikováno v:
iScience, Vol 26, Iss 10, Pp 107934- (2023)
Summary: Ovarian cancer is the deadliest gynecologic malignancy in women, with a 46% five-year overall survival rate. The objective of the study was to investigate the effects of non-homologous end-joining (NHEJ) genes on clinical outcomes of ovarian
Externí odkaz:
https://doaj.org/article/dea102a4b29e4efca5e206c474b53319
Autor:
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Abstract Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR
Externí odkaz:
https://doaj.org/article/7c21bcf75bea4e2ebab41ede567eddbb
Autor:
Pamela H Huang, Nicole E. Bowen, Baek Kim, Nour N Al Zouabi, Mark L Xu, Terence L. Wu, Yong-Lian Zhu, Elena Ratner, Z. Ping Lin, Ethan S Lavi
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Scientific Reports
Scientific Reports
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::941ce9e3b66a8cd0caeba99e850d33bf
https://doi.org/10.1038/s41598-021-87325-5
https://doi.org/10.1038/s41598-021-87325-5